RDT Products

Rare Disease Therapeutics, Inc., (RDT) works closely with the FDA’s Office of Orphan Product Development, National
Organization for Rare Disorders (NORD), the National Institutes of Health, large international pharmaceutical companies, and
patient advocacy groups to identify the unmet needs of patients with rare diseases and potential products to meet these needs.

ANTIVENOMS - FDA APPROVED PRODUCTS
Name
Status
ANASCORP [Centruroides (Scorpion) Immune F(ab’)2 (Equine)] Injection
Available
Prescribing Information
ANASCORP [Centruroides (Scorpion) Immune F(ab’)2 (Equine)] Injection
Available
Prescribing Information
ANTIVENOMS - RESEARCH PRODUCTS
Name
Status
ANAWIDOW®
Latrodectus immune F(ab’)2 antivenom
Phase 3 completed
HEMATOLOGY / ONCOLOGY - FDA APPROVED PRODUCTS
Name
Status
PURIXAN® (mercaptopurine)
Available
Prescribing Information

To report a suspected adverse reaction or to order any of our products, please call 844-472-7389.

America's First
Exclusively Orphan
Drug Company